Eger K - Search Results

1

Ligands for the affinity chromatography of mammalian thymidine kinase. 1: Strategy, synthesis and evaluation.

Beck RA, Munch-Petersen B, Dölker M, Cloos L, Tyrsted G, Eger K. Beck RA, et al. Among authors: eger k. Pharm Acta Helv. 1996 Oct;71(4):279-91. doi: 10.1016/s0031-6865(96)00029-5. Pharm Acta Helv. 1996. PMID: 8921744

2

[Feasibility of isolating and purifying thymidine kinases with the use of affinity chromatography].

Eger K, Folkers G, Beck R. Eger K, et al. Pharm Unserer Zeit. 1989 Mar;18(2):43-52. doi: 10.1002/pauz.19890180203. Pharm Unserer Zeit. 1989. PMID: 2717657 German. No abstract available.

3

Different affinity of the two forms of human cytosolic thymidine kinase towards pyrimidine analogs.

Munch-Petersen B, Tyrsted G, Cloos L, Beck RA, Eger K. Munch-Petersen B, et al. Among authors: eger k. Biochim Biophys Acta. 1995 Jul 19;1250(2):158-62. doi: 10.1016/0167-4838(95)00057-2. Biochim Biophys Acta. 1995. PMID: 7632720

4

Simplified synthesis of mono(4-aminophenyl)-3'-thymidilic acid ester used as thymidine kinase specific ligand for affinity chromatography.

Eger K, Klünder E, Beck RA, Schloz U. Eger K, et al. Pharm Res. 1993 May;10(5):771-3. doi: 10.1023/a:1018980304519. Pharm Res. 1993. PMID: 8391694 No abstract available.

5

Inhibition of protein phosphatases by Michael adducts of ascorbic acid analogues with alpha,beta-unsaturated carbonyl compounds.

Witt UG, Schultz JE, Dölker M, Eger K. Witt UG, et al. Among authors: eger k. Bioorg Med Chem. 2000 Apr;8(4):807-13. doi: 10.1016/s0968-0896(00)00013-4. Bioorg Med Chem. 2000. PMID: 10819169

6

Separation, analyses and syntheses of trimethoprim impurities.

Hess S, Dölker M, Haferburg D, Kertscher HP, Matysik FM, Ortwein J, Teubert U, Zimmermann W, Eger K. Hess S, et al. Among authors: eger k. Pharmazie. 2001 Apr;56(4):306-10. Pharmazie. 2001. PMID: 11338669

7

Studies on 2-benzyloxy-4H-3,1-benzoxazin-4-ones as serine protease inhibitors.

Gütschow M, Neumann U, Sieler J, Eger K. Gütschow M, et al. Among authors: eger k. Pharm Acta Helv. 1998 Jul;73(2):95-103. doi: 10.1016/s0031-6865(98)00003-x. Pharm Acta Helv. 1998. PMID: 9700938

8

Gene technology-based antimetabolite design: the use of an in vitro protein expression system to facilitate antimetabolite design for virally-induced human diseases and malignant conditions.

Barnett YA, Eger K, Eriksson S, Folkers G, Hansen PE, Hofbauer R, Komitowsky D, Milon A, Munch-Petersen B; European Thymidine Kinase Study Group. Barnett YA, et al. Among authors: eger k. Biotechnol Adv. 1994;12(4):663-8. doi: 10.1016/0734-9750(94)90007-8. Biotechnol Adv. 1994. PMID: 14545922

9

Synthesis and biological evaluation of new derivatives of emodin.

Teich L, Daub KS, Krügel V, Nissler L, Gebhardt R, Eger K. Teich L, et al. Among authors: eger k. Bioorg Med Chem. 2004 Nov 15;12(22):5961-71. doi: 10.1016/j.bmc.2004.08.024. Bioorg Med Chem. 2004. PMID: 15498672

10

Chiral pyrrolo[2,3-d]pyrimidine and pyrimido[4,5-b]indole derivatives: structure-activity relationships of potent, highly stereoselective A1-adenosine receptor antagonists.

Müller CE, Geis U, Grahner B, Lanzner W, Eger K. Müller CE, et al. Among authors: eger k. J Med Chem. 1996 Jun 21;39(13):2482-91. doi: 10.1021/jm960011w. J Med Chem. 1996. PMID: 8691445

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

109 results

Search Page

Filters